Etcembly

1 known investors

Etcembly builds EMLy Co-pilot, an AI platform with a conversational interface that unifies biologics design workflows—including structural modeling, variant generation, and molecule optimization—into a single tool. It serves biotechs and R&D organizations working on therapeutic candidates such as antibodies (mAbs) and TCRs.